ABIOMED (ABMD) NDR Conveys Confidence in Near Term Business Recovery, Piper Sandler Reiterates Buy
Tweet Send to a Friend
Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $425.00 price target on ABIOMED (NASDAQ: ABMD) after hosting the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
